Interleukin 6 and Liver Health in Rheumatoid Arthritis
Author Information
Author(s): Pérez-Mingan Gloria Caterine, Sierra-Merlano Rita Magola, Yepes Ismael, Vergara María Judith Palomino, Ortiz Miguel, Peña Breiner, Cano-Pérez Eder, Gómez-Camargo Doris
Primary Institution: Universidad de Cartagena
Hypothesis
This study aimed to investigate the association of IL-6 with steatotic liver disease (SLD) and liver fibrosis (LF) in rheumatoid arthritis (RA) patients.
Conclusion
IL-6 levels were related to SLD in the evaluated sample, and RA was not a risk factor for SLD or LF.
Supporting Evidence
- Cellular expression of IL-6 was significantly higher in RA compared to non-RA.
- SLD was identified in 55.3% of RA cases and 38.2% of non-RA cases.
- IL-6 levels were associated with the presence of SLD in the total population.
Takeaway
This study looked at how a substance called IL-6 affects liver health in people with rheumatoid arthritis, finding that higher levels of IL-6 are linked to liver fat but not to liver damage.
Methodology
This was a cross-sectional study that included RA and non-RA cases, evaluating IL-6 levels by flow cytometry and liver conditions by elastosonography.
Potential Biases
The study was conducted in a population characterized by a high prevalence of poverty, which may introduce bias.
Limitations
The study had a small sample size and was conducted in a single center, which may limit the generalizability of the results.
Participant Demographics
The study included 47 RA cases and 34 non-RA cases, predominantly women, with a mean age of 54 years.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website